ZBIO
Zenas BioPharma, Inc.
$27.68
+1.23 (+4.65%)
At close · Jul 7
Market Cap
$1.75B
Shares
63,133,377
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Patrick Enright | Class II director | Appointed | 2026-05-13 |
| James Boylan | Class II director | Appointed | 2026-05-13 |
| Tomas Kiselak | Board of Directors | Resigned | 2026-05-13 |